Metastatic Intracranial Hemangiopericytoma to the Spinal Column: A Case Report

Joo, Myung Sung; Rho, Young Joon; Song, Sang Woo; Koh, Young-Cho; Roh, Hong Gee; Lim, So-Dug

doi:10.14791/btrt.2016.4.2.128

Cited by 10 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although metastasis to bone from IMSCTs is rare, the spread of high-grade gliomas to the vertebral body is more common with a recent meta-analysis finding 63% of glioblastoma bone dissemination involving the vertebral column. [ 15 ] There have been reports of vertebral body metastasis of various other brain tumors including meningiomas,[ 18 ] hemangiopericytomas,[ 11 ] medulloblastomas,[ 6 ] and ependymomas. [ 6 ] The exact mechanism of vertebral bone metastasis is unknown.…”

Section: Discussionmentioning

confidence: 99%

Primary thoracic intramedullary spinal cord tumor with likely metastases of glial origin to the lumbosacral vertebrae: Illustrative case

Asante,

Lee,

Jenson

et al. 2023

Surgical Neurology International

View full text Add to dashboard Cite

Background: Metastasis of systemic neoplasms to the spine is common; however, the metastasis of primary spinal cord tumors to other regions in the body is an infrequent occurrence. A few case reports have described the metastasis of primary spinal cord tumors, and in most cases, patients were younger than 30 years of age. Case Description: We present an illustrative case of a 47-year-old female with metastatic lesions to the lumbosacral vertebrae years after the initial diagnosis of an intradural, intramedullary spinal cord tumor (IMSCT). Although the surgical biopsy of the IMSCT was nondiagnostic, the patient was not found to have a separate primary neoplastic source, and the specimens of the metastatic lesions from the lumbar vertebral body were of glial origin. Conclusion: Metastasis from primary IMSCTs is extremely rare. Distant vertebral body and intracranial metastasis are even rarer yet possible. The clinical course is highly aggressive and responds poorly to current standard treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary thoracic intramedullary spinal cord tumor with likely metastases of glial origin to the lumbosacral vertebrae: Illustrative case

Asante,

Lee,

Jenson

et al. 2023

Surgical Neurology International

View full text Add to dashboard Cite

show abstract

“…The tumor was present one year prior to the initial manifestation of the symptoms, when the patient noticed a growth of the neoplasm with occasional bleeding. The neoplasm was described as an irregular, oval-shaped mass, the lymphatics, and hematogenous pathway, which is the most frequent route 21 .…”

Section: Case Reportmentioning

confidence: 99%

Large hemangiopericytoma of the shoulder: A case report

et al. 2022

View full text Add to dashboard Cite

Introduction: Hemangiopericytoma is a rare tumor arised from the pericytes, contractile spindle cells that surround the capillaries and post-capillary venules. The tumor was found equally among males and females. Case report: We report a case of a 63-year-old female who presented a giant painful mass on her right shoulder that occurred one year before admission. Limited range of motion and a sense of tingling along the affected arm was present also. An irregular, oval-shaped mass, colored dark-red, with signs of necrosis was the maximal diameter of 14cm. Routine laboratory analyzes showed results within the range of referenced values. Lung X-ray and ultrasonographic examination of the abdomen showed no signs of secondary tumor deposits, and no osteo-muscular lesions in the affected region. Ultrasonographic examination of the neck and right axillary region showed no signs of regional metastases. The surgical excision of the entire tumor was performed, with the associated subcutaneous tissue and a part of fascia underneath. Results of the histopathological analysis confirmed the diagnosis of hemangiopericytoma. The specimen showed no signs or elements of the neoplastic tissue on the edges of the resection lines. 3 years after the operation, there was found no signs of tumor relapses, regional or systemic metastases. Conclusion: Considering that there are no official clinical guides and protocols for hemangiopericytoma management, as well as the occurrence of cutaneous and subcutaneous hemangiopericytomas is exceptionally rare, more extensive research in this field and more described cases are need to gain a better understanding of that issue.

show abstract

“…122,123 A comprehensive search reveals a total of 17 studies now published reporting the utility of SRS for recurrent and residual HPC, summarized in Table 2. 10,14,17,24,27,28,47,98,103,104,106,115,[124][125][126][127] The first of the reports is by Coffey et al 14 describing a small cohort of 11 lesions in five patients, all receiving prior craniotomy (three also received prior EBRT with doses of 50-53 Gy). Prescribed margin doses reported ranged 12-18 Gy, and the mean follow-up period was 14.8 months.…”

Section: Stereotactic Radiosurgerymentioning

confidence: 99%

Nervous System Hemangiopericytoma

Cohen-Inbar

2019

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

Abstract:The management of patients harboring central nervous system (CNS) hemangiopericytomas (HPCs) is a partially answered challenge. These are rare locally aggressive lesions, with potential for local recurrence, distal neural metastasis (DNM), and extraneural metastasis (ENM). Resection, when feasible, remains the initial treatment option, providing histological diagnosis and immediate relief of tumor-related mass effect. Patients receiving surgery alone or surgery and external beam radiotherapy (EBRT) show improved overall survival (OS) and progression-free survival as compared to those undergoing a biopsy alone (p = 0.01 and p = 0.02, respectively). Yet, in many instances, patient and tumor-related parameters preclude complete resection. EBRT or stereotactic radiosurgery (SRS) shares a significant role in achieving local tumor control, not shown to impact OS in HPC patients. The benefits of SRS/EBRT are clearly limited to improved local tumor volume control and neurologic function, not affecting DNM or ENM development. SRS provides acceptable rates of local tumor volume control coupled with treatment safety and a patient-friendly apparatus and procedure. Single-session SRS is most effective for lesions measuring <2 cm in their largest diameter (10 cm3 volume), with prescription doses of at >15 Gy. Systemic HPC disease is managed with various chemotherapeutic, immunotherapeutic, and anti-angiographic agents, with limited success. We present a short discussion on CNS HPCs, focusing our discussion on available evidence regarding the role of microsurgical resection, EBRT, SRS, chemotherapy, and immunotherapy for upfront, part of adoptive hybrid surgery approach or for recurrent HPCs.

show abstract

Metastatic Intracranial Hemangiopericytoma to the Spinal Column: A Case Report

Cited by 10 publications

References 21 publications

Primary thoracic intramedullary spinal cord tumor with likely metastases of glial origin to the lumbosacral vertebrae: Illustrative case

Primary thoracic intramedullary spinal cord tumor with likely metastases of glial origin to the lumbosacral vertebrae: Illustrative case

Large hemangiopericytoma of the shoulder: A case report

Nervous System Hemangiopericytoma

Contact Info

Product

Resources

About